This is a multi-center, prospective, pilot cohort study, performed in the Intensive Care Units (ICUs) of the Ghent University Hospital, CHU Liège, University Hospital Brussels, and University Hospital Munster.~Each group will contain 20 subjects; in total there will be 40 subjects 2 groups of 20 patients GROUP 1: VV-ECMO n = 20 GROUP 2: VA-ECMO n = 20~Demographics: age, sex, comorbidities, medication, reason for ECMO therapy~Simplified Acute Physiology Score (SAPS) 3 at time of ICU admission.~Components of the Sequential Organ Failure Assessment score daily (based on worst value of each component of the score)~ECMO characteristics (place of cannulation, type of cannulas, oxygenator, bloodflow, gasflow and pressure registrations)~Incidence and severity of bleeding, scored according to the GUSTO and BARC scores~Coagulation profile: At inclusion (before heparine infusion is started), 2h after start of therapy, 24h, and 48h, and at specific moments of clinical suspicion of profound altered hemostasis. We defined a coagulation profile as a set of tests that includes~prothrombin time (PT), international normalized ratio (INR)~activated partial thromboplastin time (aPTT) and heparin ratio~the fibrinogen level~platelets~ACT (iACT®, …)~D-dimer~ROTEM (extem, intem, heptem) or TEG (Utrecht)~AT III~anti Xa~Temperature daily (H/L) (core)~Patient characteristics that may influence coagulation or the results of coagulation tests: body weight, Body Mass Index, drugs, C-reactive protein (as a marker for inflammation), Hemoglobin level, LDH, unconjugated bilirubin, (or haptoglobine or plasma free haemoglobin, if tested)~Heparin dose
To evaluate change in coagulation tests during a 48-h period after initiation VV-ECMO and VA-ECMO.~(ECMO= Extra Corporeal Membrane Oxygenator) Assessment of bleeding during Veno-Venous Extracoporeal Membrane Oxygenator (VV-ECMO) and Veno-Arterial Extracoporeal Membrane Oxygenator (VA-ECMO).